PeterCEnzingerMD

Oncology • Boston, MA

Assistant Professor of Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Enzinger is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Enzinger's full profile

Already have an account?

Office
44 Binney St
Danafarber Cancer Inst
Boston, MA 02115
Phone+1 617-632-6855

Fax+1 617-632-5370

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
University of RochesterResidency, Internal Medicine, 1992 - 1995
The Warren Alpert Medical School of Brown UniversityClass of 1992

Certifications & Licensure

MA State Medical License 1999 - 2025
NY State Medical License 1995 - 2006
American Board of Internal Medicine Medical Oncology

Clinical Trials

Avastin and Taxotere for Esophagogastric Cancer Start of enrollment: 2004 Aug 01
Completed
Phase 2
Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer Start of enrollment: 2002 Jan 01
Completed
Phase 2
Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer Start of enrollment: 2001 Aug 01
Completed
Phase 2
Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer Start of enrollment: 2004 Aug 01
Completed
Phase 2
Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies Start of enrollment: 2001 Nov 01
Completed
Phase 1
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2006 Sep 15
Completed
Phase 2
Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer Start of enrollment: 2006 Sep 01
Completed
Phase 2
Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer Start of enrollment: 2009 Jul 01
Completed
Phase 2
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer Start of enrollment: 2011 Feb 01
Active, not recruiting
Phase 2
FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer Start of enrollment: 2013 Jan 01
Completed
Phase 2
Pembrolizumab in Refractory Advanced Esophageal Cancer Start of enrollment: 2017 Jan 18
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

670 citations
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Jaffer A Ajani, Thomas A D'Amico, David J Bentrem, Joseph Chao, David Cooke
Journal of the National Comprehensive Cancer Network. 2022-02-01
100 citations
Chemotherapy in esophageal cancer
Peter C. Enzinger, David H. Ilson, David P. Kelsen
Seminars in Oncology. 1999-10-01
105 citations
Identification of Potentially Avoidable Hospitalizations in Patients With GI Cancer
Gabriel A. Brooks, Thomas A. Abrams, Jeffrey A. Meyerhardt, Peter C. Enzinger, Karen Sommer
Journal of Clinical Oncology. 2014-02-20

Lectures

Pre/Post-Op Chemotherapy
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Merck, Roche and Bristol Myers Nab 4 of 6 Positive ODAC Votes for ‘Dangling’ Accelerated ApprovalsApril 29th, 2021
FDA Approves Pembrolizumab plus Platinum- & Fluoropyrimidine-Based Chemotherapy for Treatment of Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) CarcinomaMarch 23rd, 2021
FDA Approves Merck’s KEYTRUDA® (Pembrolizumab) plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) CarcinomaMarch 23rd, 2021
Join now to see all